Men treated for prostate cancer after surgery now have clearer evidence that extending hormone therapy from six months to two ...

Survivorship in metastatic prostate cancer is seen as chronic management, focusing on quality of life through physical and emotional management. Carotuximab combined with Erleada shows a favorable ...

The FDA Just Approved a New Drug for an Aggressive Form of Prostate Cancer — and It Targets the Disease in a Way No Approved ...

Many patients with metastatic castration-resistant prostate cancer are not receiving bone-modifying agents, despite guideline endorsement.

Prostate cancer has distinct genetic properties in different groups of men that can be targeted to improve patient outcomes, UVA Cancer Center researchers have discovered. Based on new findings in ...

Only about 6% of men have had a documented discussion with their primary care doctor about prostate cancer screening, even ...

Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical trials for ovarian and bile duct cancer, according to research published in ...

As part of its Speaking Out video series, CURE talked to Dr. Brian Keith McNeil, on behalf of ZERO Prostate Cancer, about navigating treatment option in prostate cancer. Advancements in prostate ...

Not all cancers are alike, especially when it comes to prostate cancer. “The guidelines recommend they go on active surveillance rather than getting treated. For many of them, it’s really unlikely ...

For men with genitourinary malignancies, such as prostate cancer, examining the external genital area is essential. While this may seem routine, it remains a crucial recommendation, as illustrated by ...

Androgen deprivation therapy (ADT) is the main treatment for advanced prostate cancer, but toxic effects can affect both physical and mental health. Awareness of these adverse effects cause some men ...

Novel therapies for metastatic castration-resistant prostate cancer (mCRPC) have improved patient outcomes. However, there is uncertainty on the optimal selection of therapeutic agents for subsequent ...